BioSante’s Cancer Drug Shows Significant Gain (BPAX)
Drug maker BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) has released the results of a Phase Ib study of its pancreatic cancer vaccine GVAX indicating that, when used in combination with another drug, patients survive longer. The drug combination “increased the median…
Drug maker BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) has released the results of a Phase Ib study of its pancreatic cancer vaccine GVAX indicating that, when used in combination with another drug, patients survive longer. The drug combination “increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma survival rate” by 60%, from 3.3 months to 5.5 months. The study also showed a jump in one-year survival from 7% to 27%.
In the pre-market this morning, BioSante shares are up about 25% at $0.86.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
